Indian Pharma Market registers 7.2 percent growth in October: AIOCD-AWACS Report
New Delhi: The Indian Pharmaceutical Market (IPM) has registered a decline in growth for the month of October as industry sales rose only 7.2 percent at Rs 15338 crore in October, as per the data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).The industry sales rose as 7.2 percent (in terms of Value) at Rs 15338 crore in October compared to the same...
New Delhi: The Indian Pharmaceutical Market (IPM) has registered a decline in growth for the month of October as industry sales rose only 7.2 percent at Rs 15338 crore in October, as per the data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).
The industry sales rose as 7.2 percent (in terms of Value) at Rs 15338 crore in October compared to the same month in 2021. That compares with a 5.5 percent year-on-year increase in October 2021 and 13% growth in September 2022.
The Moving Annual Total (MAT) or 12-month rolling sales of overall pharma products rose 6.4 percent at Rs 176671 crore in October.
As per the All India Organization of Chemists and Druggists' (AIOCD-AWACS) market research, among the top therapies, Cardiac, Derma, Respiratory and Gynaec have shown a robust value growth. Anti-infectives is the only therapy among the top therapies that has shown value degrowth of -7.9 percent valued at Rs 22011 crore.
Quarterly Growth Driver QTR trend showed volumes fell 0.9% year-on-year. New product launches registered 1.8% growth, while prices increased by 6.3%.
Overall, the acute-therapy segment grew 5.3% year-on-year, compared to 8.1% growth in October 2021, the AIOCD data cited.
Further, chronic therapy, which comprises medicines for long-term ailments such as cardiac ailments and diabetes, and the sub-chronic segment saw growth of around 8.8% and 8.7%, respectively. That compares to 1.9% and 2.9% growth in October 2021.
Sales of gynecological products rose the most by 16.4%, followed by an 11.8% growth in the dermatological segment and a 10.6% growth in the respiratory segment.
Cardiac segments grew by 9.8%, followed by pain, neurological/CNS segments, and vitamins in the range of 7%–8%.
Gastroenterology and anti-diabetic segments grew 5.6% and 5%, respectively, over the year-ago period, while sales of anti-infectives declined 1.2%.
Also Read: Indian Pharma Market Sees 12.1 Percent Growth In August: AIOCD-AWACS Report
In terms of monthly sales, Sun Pharma + Ranbaxy topped the top 20 Corporates list with growth of 8.55 percent at Rs 1250 crore followed by Abbott + Abbott HC + Novo and Cipla with a growth of 6.49% and 5.01% respectively.
Meanwhile, the top three selling brands in India in October were Manforce manufactured by Mankind Pharma; Augmentin, commonly used to treat infections of the urinary tract, respiratory tract, ear, sinuses, and skin, marketed by GSK and Foracort by Cipla.
